

VPA10804/005/001

ALPHA JECT micro 6 emulsion for injection for atlantic salmon

Variation	Summary	Date
Vet - G.I.15 z)	VRA-R - Vet - G.I.15 z) - - Vet - G.I.15 z) - Changes to the labelling or the package leaflet which are not connected with the summary of product characteristics - Other changes under this code level, e.g. variations outlined in section 6 and 7 of this guidance	12/12/25
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	15/07/25
Vet - B46	VNRA - Vet - B46 - - Vet - B46 - Submission of an updated Ph. Eur. TSE CEP of an already approved manufacturer for:— active substance;— starting material, reagent, intermediate used in the manufacturing process of the active substance;— excipient	01/07/25
Vet - C1	VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	21/01/25
Vet - B38	VNRA - Vet - B38 - Change in pack size (number of units e.g. tablets, ampoules, etc. in a pack) within the range of the currently approved pack size - B38 Changes to the quality part of the dossier: Change in pack size (number of units e.g. tablets, ampoules, etc. in a pack) within the range of the currently approved pack size. In cases where a given pack size has received an individual marketing authorisation which is separate to the marketing authorisation for other pack sizes of the same product, the change of the former will not be a variation according to Article 61, but a variation according to Article 62 of Regulation (EU) 2019/6	24/10/24
Vet - F.I.a.4 a)	VRA-S - Vet - F.I.a.4 a) - a) Widening of the approved in-process test limits, which may have a significant effect on the overall quality of the active substance - F.I.a.4 a) Quality	03/10/24

	Changes - Active Substance - Manufacture -Change to in-process tests or limits applied during the manufacture of the active substance - Widening of the approved in-process test limits, which may have a significant effect on the overall quality of the active substance	
Vet - F.I.a.2 z)	VRA-R - Vet - F.I.a.2 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.I.a.2 z) Quality Changes - Active Substance - Manufacture - Changes in the manufacturing process of the active substance - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	08/08/24
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	11/07/24
Vet - F.III.1 b) 1.	VRA-S - Vet - F.III.1 b) 1. - b) European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient 1. New/updated certificate from an already- approved/new manufacturer using materials of human or animal origin for which an assessment of the risk with respect to potential contamination with adventitious agents is required - F.III.1 b) 1. Quality Changes - CEP/TSE/MONOGRAPHS - Submission of a new or updated Ph. Eur. certificate of suitability or deletion of Ph. Eur. certificate of suitability: -For an active substance -For a starting material/reagent/intermediate used in the manufacturing process of the active substance -For an excipient European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient - New/updated certificate from an already- approved/new manufacturer using materials of human or animal origin for which an assessment of the risk with respect to potential contamination with adventitious agents is required	03/04/24
Vet - F.III.1 b) 1.	VRA-S - Vet - F.III.1 b) 1. - b) European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient 1. New/updated certificate from an already- approved/new manufacturer using materials of human or animal origin for which an assessment of the risk with respect to potential contamination with adventitious agents is required - F.III.1 b) 1. Quality Changes - CEP/TSE/MONOGRAPHS - Submission of a new or updated Ph. Eur. certificate of suitability or deletion of Ph. Eur. certificate of suitability: -For an active substance -For a starting material/reagent/intermediate used in the manufacturing process of the active substance -For an excipient European Pharmacopoeial TSE Certificate of suitability for an active	03/04/24

	substance/starting material/reagent/ intermediate/or excipient - New/updated certificate from an already- approved/new manufacturer using materials of human or animal origin for which an assessment of the risk with respect to potential contamination with adventitious agents is required	
Vet - F.III.1 b) 1.	VRA-S - Vet - F.III.1 b) 1. - b) European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient 1. New/updated certificate from an already- approved/new manufacturer using materials of human or animal origin for which an assessment of the risk with respect to potential contamination with adventitious agents is required - F.III.1 b) 1. Quality Changes - CEP/TSE/MONOGRAPHS - Submission of a new or updated Ph. Eur. certificate of suitability or deletion of Ph. Eur. certificate of suitability: -For an active substance -For a starting material/reagent/intermediate used in the manufacturing process of the active substance -For an excipient European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient - New/updated certificate from an already- approved/new manufacturer using materials of human or animal origin for which an assessment of the risk with respect to potential contamination with adventitious agents is required	03/04/24
Vet - F.III.1 b) 1.	VRA-S - Vet - F.III.1 b) 1. - b) European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient 1. New/updated certificate from an already- approved/new manufacturer using materials of human or animal origin for which an assessment of the risk with respect to potential contamination with adventitious agents is required - F.III.1 b) 1. Quality Changes - CEP/TSE/MONOGRAPHS - Submission of a new or updated Ph. Eur. certificate of suitability or deletion of Ph. Eur. certificate of suitability: -For an active substance -For a starting material/reagent/intermediate used in the manufacturing process of the active substance -For an excipient European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient - New/updated certificate from an already- approved/new manufacturer using materials of human or animal origin for which an assessment of the risk with respect to potential contamination with adventitious agents is required	03/04/24
Vet - F.I.a.2 b)	VRA-S - Vet - F.I.a.2 b) - b) The change refers to a biological / immunological substance or use of a different chemically derived substance in the manufacture of a biological/immunological substance, which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol - F.I.a.2 b) Quality Changes - Active Substance - Manufacture - Changes in the manufacturing process of the active substance - The change refers to a biological / immunological substance or use	25/03/24

	of a different chemically derived substance in the manufacture of a biological/immunological substance, which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol	
Vet - F.I.a.2 b)	VRA-S - Vet - F.I.a.2 b) - b) The change refers to a biological / immunological substance or use of a different chemically derived substance in the manufacture of a biological/immunological substance, which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol - F.I.a.2 b) Quality Changes - Active Substance - Manufacture - Changes in the manufacturing process of the active substance - The change refers to a biological / immunological substance or use of a different chemically derived substance in the manufacture of a biological/immunological substance, which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol	25/03/24
Vet - B3 a)	VNRA - Vet - B3 a) - a) Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier) - B3 a) Changes to the quality part of the dossier: Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier)	07/12/23
Vet - F.I.a.4 z)	VRA-R - Vet - F.I.a.4 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.I.a.4 z) Quality Changes - Active Substance - Manufacture -Change to in-process tests or limits applied during the manufacture of the active substance - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	16/05/23
Vet - F.II.d.2 a)	VRA-S - Vet - F.II.d.2 a) - a) Substantial change to, or replacement of, a biological/ immunological/ immunochemical test method or a method using a biological reagent or replacement of a biological reference preparation not covered by an approved protocol - F.II.d.2 a) Quality Changes - Finished Product -Control of finished product - Change in test procedure for the finished product - Substantial change to, or replacement of, a biological/ immunological/ immunochemical test method or a method using a biological reagent or replacement of a biological reference preparation not covered by an approved protocol	21/04/23
Vet - F.II.d.2 a)	VRA-S - Vet - F.II.d.2 a) - a) Substantial change to, or replacement of, a biological/ immunological/ immunochemical test method or a method using a biological reagent or replacement of a biological reference preparation not covered	21/04/23

	by an approved protocol - F.II.d.2 a) Quality Changes - Finished Product -Control of finished product - Change in test procedure for the finished product - Substantial change to, or replacement of, a biological/ immunological/ immunochemical test method or a method using a biological reagent or replacement of a biological reference preparation not covered by an approved protocol	
Vet - F.II.b.1 e)	VRA-S - Vet - F.II.b.1 e) - e) Change in supplier of sterilised primary container components, which are to be used in the aseptic manufacture of veterinary medicinal products - F.II.b.1 e) Quality Changes - Finished Product -Manufacture - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - Change in supplier of sterilised primary container components, which are to be used in the aseptic manufacture of veterinary medicinal products	31/01/23
Vet - F.I.a.3 b)	VRA-R - Vet - F.I.a.3 b) - b) The scale for a biological/immunological active substance is increased/decreased without process change (e.g. duplication of line) - F.I.a.3 b) Quality Changes - Active Substance - Manufacture -Change in batch size (including batch size ranges) of active substance or intermediate used in the manufacturing process of the active substance - The scale for a biological/immunological active substance is increased/decreased without process change (e.g. duplication of line)	13/12/22
Vet - F.I.a.2 z)	VRA-S - Vet - F.I.a.2 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.I.a.2 z) Quality Changes - Active Substance - Manufacture - Changes in the manufacturing process of the active substance - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	12/08/22
Vet - F.I.a.2 z)	VRA-S - Vet - F.I.a.2 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.I.a.2 z) Quality Changes - Active Substance - Manufacture - Changes in the manufacturing process of the active substance - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	12/08/22
B.III.1.a.2	IA - B.III.1.a.2 - 2. Updated certificate from an already approved manufacturer - B.III.1.a.2 - QUALITY CHANGES - CEP/TSE/MONOGRAPHS - Submission of a new or updated Ph. Eur. Certificate of suitability or deletion of Ph. Eur. certificate of suitability: For an active substance For a starting material/reagent/intermediate used in the manufacturing process of the active substance For an excipient - European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer	01/02/22